TAU: Clinical Trials

12 trials of TAU, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 2 recruiting, 1 suspended, 1 terminated. 12 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 312Completed 7, Recruiting 2, Suspended 1, Terminated 1, Unknown 1
Phase 23Completed 1, Terminated 1, Unknown 1

Follow TAU: new trials by email Literature Review of TAU trials Research Report on TAU

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI)
Quetiapine Fumarate, TAU - Mild Traumatic Brain Injury
Phase 3RecruitingFoundation for Advancing Veterans' Health Research1462024-07-092025-07-11
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
MORE, SMP, TAU - Opioid Use, Pain
Phase 3RecruitingRutgers, The State University of New Jersey4502023-09-042025-07-30
Integrated Digital Intervention for Alcohol Use Disorder
Mobile health application, Medical Management - Alcohol Use Disorder
Phase 2 / Phase 3CompletedQuit Genius2422023-01-012025-11-20
Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment
Buprenorphine/Naloxone, Treatment as usual - Opioid Use
Phase 3SuspendedFriends Research Institute, Inc.3202022-07-012026-11-12
A Study to Evaluate the Safety and Effectiveness of a Digital Therapeutic
OTX-202, OTX-000, Treatment as Usual - Suicide, Attempted, Suicidal Ideation
Phase 2 / Phase 3TerminatedOui Therapeutics, Inc.3562022-04-072025-06-12
Cognitive Effects of Adjuvant Vortioxetine in Early Schizophrenia
Vortioxetine, Usual Antipsychotic Treatment - Cognitive Impairment With Primary Psychotic Disorder, Negative Symptoms With Primary Psychotic Disorder
Phase 2 / Phase 3UnknownFundación Pública Andaluza para la gestión de la Investigación en Sevilla372022-01-202024-02-26
Cost-utility and Biological Underpinnings of MBSR in Fibromyalgia Syndrome
MBSR, FibroQol, TAU - Fibromyalgia Syndrome
Phase 3CompletedFundació Sant Joan de Déu2252016-01-012019-10-14
Integrated Cognitive Behavioral Therapy (ICBT) for Posttraumatic Stress Disorder (PTSD) and Substance Use Disorders
Integrated Cognitive Behavioral Therapy, Treatment-as-usual - Stress Disorder, Post-Traumatic, Substance-Related Disorders
Phase 3CompletedDartmouth-Hitchcock Medical Center562011-02-012015-10-26
Cognitive Behavioral Therapy (CBT) for Posttraumatic Stress Disorder (PTSD) in Community Addiction Treatment
Cognitive Behavioral Therapy, Individual Addiction Counseling, Treatment-as-usual - Stress Disorders, Post-Traumatic, Substance-Related Disorders
Phase 3CompletedDartmouth-Hitchcock Medical Center4432010-12-012015-02-16
School-based Treatment for Anxious Children
Cognitive behavioral therapy (CBT), Treatment as usual (TAU) - Anxiety Disorders
Phase 3CompletedJohns Hopkins University402006-10-012013-09-24
Identification and Therapy of Postpartum Depression
Care Management for Postpartum Depression, TAU - Depression
Phase 3CompletedUniversity of Pittsburgh6282006-08-012013-10-07
Brief Strategic Family Therapy for Adolescent Drug Abusers
Brief Strategic Family Therapy (BSFT), Treatment as Usual - Substance Abuse
Phase 3CompletedUniversity of Miami4802004-08-012015-07-07

Conditions studied

Stress Disorders, Post-Traumatic (3)  ·  Substance-Related Disorders (3)  ·  Behavior, Addictive (2)  ·  Alcoholism (1)  ·  Anxiety Disorders (1)  ·  Brain Concussion (1)  ·  Depression (1)  ·  Depression, Postpartum (1)  ·  Fibromyalgia (1)  ·  Pain (1)  ·  Post-Concussion Syndrome (1)  ·  Suicidal Ideation (1)  ·  Suicide, Attempted (1)

Sponsors

Dartmouth-Hitchcock Medical Center (2)  ·  Foundation for Advancing Veterans' Health Research (1)  ·  Friends Research Institute, Inc. (1)  ·  Fundació Sant Joan de Déu (1)  ·  Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1)  ·  Johns Hopkins University (1)  ·  Oui Therapeutics, Inc. (1)  ·  Quit Genius (1)  ·  Rutgers, The State University of New Jersey (1)  ·  University of Miami (1)  ·  University of Pittsburgh (1)

Countries

United States (10)  ·  Spain (2)  ·  Puerto Rico (1)

Top investigators

Mark P. McGovern, Ph.D. (2)  ·  Benedicto Crespo Facorro, Professor (1)  ·  Eric Garland, Ph (1)  ·  Golda Ginsburg, PhD (1)  ·  Jose Szapocznik, Ph.D. (1)  ·  Juan V. Luciano, PhD (1)  ·  Katherine L. Wisner, MD, RN (1)

Results publications

PMID 15850502, PMID 19032530, PMID 19470315, PMID 21075957, PMID 21381158, PMID 21967492, PMID 22439295, PMID 23487258, PMID 23795871, PMID 25462653, PMID 25846251, PMID 26059839, PMID 26286351, PMID 26921267, PMID 27920321, PMID 28796940, PMID 29540927, PMID 30538599, PMID 31356450, PMID 35222735, PMID 38907675, PMID 39566056, PMID 40779267

NIH funding

5RC2DA028864 (1), R01DA027650 (1), R01DA030102 (1), R01DA056537 (1), R01MH071825 (1), R34MH074552 (1), R42MH123357 (1), U10DA013720 (1)